Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador
Background: In 2005, bevacizumab was approved by Health Canada for patients with metastatic colorectal cancer (mcrc). Newfoundland and Labrador was one of the first Canadian provinces to fund this agent in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) chemotherapy. In this analys...
Published in: | Current Oncology |
---|---|
Main Authors: | , , , , |
Format: | Text |
Language: | English |
Published: |
Multidisciplinary Digital Publishing Institute
2010
|
Subjects: | |
Online Access: | https://doi.org/10.3747/co.v17i5.592 |
id |
ftmdpi:oai:mdpi.com:/1718-7729/17/5/592/ |
---|---|
record_format |
openpolar |
spelling |
ftmdpi:oai:mdpi.com:/1718-7729/17/5/592/ 2023-08-20T04:08:04+02:00 Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador G. Dranitsaris S. Edwards J. Edwards M. Leblanc R. Abbott 2010-10-01 application/pdf https://doi.org/10.3747/co.v17i5.592 EN eng Multidisciplinary Digital Publishing Institute https://dx.doi.org/10.3747/co.v17i5.592 https://creativecommons.org/licenses/by/4.0/ Current Oncology; Volume 17; Issue 5; Pages: 12-16 bevacizumab colorectal cancer metastatic safety folfiri Text 2010 ftmdpi https://doi.org/10.3747/co.v17i5.592 2023-08-01T00:45:51Z Background: In 2005, bevacizumab was approved by Health Canada for patients with metastatic colorectal cancer (mcrc). Newfoundland and Labrador was one of the first Canadian provinces to fund this agent in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) chemotherapy. In this analysis, the entire provincial bevacizumab sample for the first 2 years was assessed for overall safety and efficacy. Methods: The medical records of 43 patients with mcrc who had received FOLFIRI with bevacizumab were identified and reviewed. The longitudinal data collection format that was adopted assessed occurrences of adverse events after each cycle of treatment. Toxicity outcomes such as gastrointestinal (GI) perforations, bleeding, diarrhea, myelosuppression, proteinuria, and venous thromboembolic events (VTES) were collected and graded using the U.S. National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 3.0. Time to treatment failure (TTF) and overall survival (os) were determined using the Kaplan–Meier method. Results: Overall, the 43 study patients received 398 cycles of anticancer therapy (median: 6 cycles; range: 1–24 cycles). No GI perforations were identified. However, 4 bleeding events occurred (9.3%), 3 requiring permanent discontinuation of bevacizumab. Also, 6 grade 3 or 4 VTES occurred (14.0%), 3 of which required a hospital admission. In addition, grades 3 and 4 diarrhea, febrile neutropenia, and proteinuria showed cumulative incidences of 11.6%, 2.3%, and 2.3% respectively. Median TTF was 6.3 months; median os was 24.4 months. Conclusions: Bevacizumab in combination with FOLFIRI appears to be well tolerated, and efficacy is consistent with trial reports. However, patients should be closely monitored to avoid potentially serious events such as bleeding and VTES. Text Newfoundland MDPI Open Access Publishing Canada Meier ENVELOPE(-45.900,-45.900,-60.633,-60.633) Newfoundland Current Oncology 17 5 12 16 |
institution |
Open Polar |
collection |
MDPI Open Access Publishing |
op_collection_id |
ftmdpi |
language |
English |
topic |
bevacizumab colorectal cancer metastatic safety folfiri |
spellingShingle |
bevacizumab colorectal cancer metastatic safety folfiri G. Dranitsaris S. Edwards J. Edwards M. Leblanc R. Abbott Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador |
topic_facet |
bevacizumab colorectal cancer metastatic safety folfiri |
description |
Background: In 2005, bevacizumab was approved by Health Canada for patients with metastatic colorectal cancer (mcrc). Newfoundland and Labrador was one of the first Canadian provinces to fund this agent in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) chemotherapy. In this analysis, the entire provincial bevacizumab sample for the first 2 years was assessed for overall safety and efficacy. Methods: The medical records of 43 patients with mcrc who had received FOLFIRI with bevacizumab were identified and reviewed. The longitudinal data collection format that was adopted assessed occurrences of adverse events after each cycle of treatment. Toxicity outcomes such as gastrointestinal (GI) perforations, bleeding, diarrhea, myelosuppression, proteinuria, and venous thromboembolic events (VTES) were collected and graded using the U.S. National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 3.0. Time to treatment failure (TTF) and overall survival (os) were determined using the Kaplan–Meier method. Results: Overall, the 43 study patients received 398 cycles of anticancer therapy (median: 6 cycles; range: 1–24 cycles). No GI perforations were identified. However, 4 bleeding events occurred (9.3%), 3 requiring permanent discontinuation of bevacizumab. Also, 6 grade 3 or 4 VTES occurred (14.0%), 3 of which required a hospital admission. In addition, grades 3 and 4 diarrhea, febrile neutropenia, and proteinuria showed cumulative incidences of 11.6%, 2.3%, and 2.3% respectively. Median TTF was 6.3 months; median os was 24.4 months. Conclusions: Bevacizumab in combination with FOLFIRI appears to be well tolerated, and efficacy is consistent with trial reports. However, patients should be closely monitored to avoid potentially serious events such as bleeding and VTES. |
format |
Text |
author |
G. Dranitsaris S. Edwards J. Edwards M. Leblanc R. Abbott |
author_facet |
G. Dranitsaris S. Edwards J. Edwards M. Leblanc R. Abbott |
author_sort |
G. Dranitsaris |
title |
Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador |
title_short |
Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador |
title_full |
Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador |
title_fullStr |
Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador |
title_full_unstemmed |
Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador |
title_sort |
bevacizumab in combination with folfiri chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of newfoundland and labrador |
publisher |
Multidisciplinary Digital Publishing Institute |
publishDate |
2010 |
url |
https://doi.org/10.3747/co.v17i5.592 |
long_lat |
ENVELOPE(-45.900,-45.900,-60.633,-60.633) |
geographic |
Canada Meier Newfoundland |
geographic_facet |
Canada Meier Newfoundland |
genre |
Newfoundland |
genre_facet |
Newfoundland |
op_source |
Current Oncology; Volume 17; Issue 5; Pages: 12-16 |
op_relation |
https://dx.doi.org/10.3747/co.v17i5.592 |
op_rights |
https://creativecommons.org/licenses/by/4.0/ |
op_doi |
https://doi.org/10.3747/co.v17i5.592 |
container_title |
Current Oncology |
container_volume |
17 |
container_issue |
5 |
container_start_page |
12 |
op_container_end_page |
16 |
_version_ |
1774720130433941504 |